ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Immunotherapy Shrinks Tumors In Phase I Study at St. Jude

May 30, 2014

Controversy Continues, Scientists, Advocates, Clinicians Say

January 31, 1997

Samuel Broder Plans To Leave Celera.

September 10, 2010

Stories On Proscar Cause Confusion In Prostate Cancer Prevention Trial

September 6, 1996

Broder Sworn In, Cites Three ‘Teachers’ – Gallo, Waldermann, DeVita

January 27, 1989

NCI, NHGRI Fund Two More Components of TCGA Project.

October 27, 2006